Form 4: Tyra Biosciences Director Acquires 37,200 Shares Through Option Grant

Stephen Michael Rothenberg, a director at Tyra Biosciences, acquired 37,200 shares of common stock through an option grant on May 7, 2024.

Summary

• Stephen Michael Rothenberg, a director of Tyra Biosciences, acquired 37,200 shares of common stock via an option grant.
• The transaction occurred on May 7, 2024, with the option priced at $17.94.
• The options vest monthly over three years, starting May 7, 2024, contingent upon continuous service to Tyra Biosciences.
• Following the transaction, Rothenberg directly owns 37,200 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of an option grant to a director. While insider buying can be seen as positive, it's part of a compensation package and doesn't necessarily indicate strong bullish sentiment.

Positives

• A director's acquisition of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors and officers, regarding their holdings of the company's securities.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it reflects a director's increased stake in the company.

Key Dates